ES Hickman Bioconsulting Ltd.
Strategic focus, innovation and delivery across biology and drug discovery
About the company
ES Hickman Bioconsulting Ltd was set up by Dr Emma Hickman to support biotech and life science investors. Emma uses her extensive expertise from the biotech and pharma industries to manage some of the skills gaps, communication barriers and capacity shortfalls faced by biotech companies during periods of rapid growth. She also performs scientific due-diligence for investors who are looking to evaluate potential value and risk associated with new technologies.
Emma is passionate about growing biotech and engages in both short and long term projects with a variety of life science clients. Work with Emma to build your drug discovery workflows, prioritize the most innovative targets and deliver a compelling scientific narrative for your investors and strategic partners.
How can I help you?
Vision:
In both fundraising and partnership negotiations, a clear value and impact message is key to a successful outcome. Using her biological and industry insight, and her first-hand fundraising experience, Emma will help to define and articulate a compelling vision for your technology. She'll also help you to incorporate it into your investment or partnership strategy and your company culture.
Strategy and Execution:
Companies require access to deep expertise from the outset but may initially lack the scale to justify full time roles. Short-term capacity bottlenecks can also arise within existing skill-sets, created by events such as fundraising cycle, new partnerships and staff turnover. A consultant with broad strategic and practical drug discovery experience can provide expertise and support on a flexible, temporary and/or part time basis as dictated by business needs. They can work alongside your existing team to keep things moving smoothly at with minimal commitment and risk.
Emma is comfortable flexing between big picture strategic thinking and experimental/operational detail. She has built target/drug discovery workflows and multi-disciplinary teams from 'scratch', and has experience in mentoring scientific staff during the challenging cultural transition from an academic environment to an industrial one.
Furthermore:
Emma has an extensive professional network from which to draw on. She can provide individual recommendations and/or build a multi-disciplinary advisory team wherever they are needed to support you on your journey.
Let’s Talk:
If this resonates, please get in touch. You can discuss possible areas of need on a free, no-obligation basis. Both short term and longer term projects are welcome, and can range in duration from a few focused hours on ad hoc basis to longer-term ongoing interactions.
Expertise
Emma is a target identification, target validation and drug discovery specialist with more than 20 years of combined pharmaceutical and biotechnology experience. She brings energy, critical thinking and deep technical expertise to deliver the highest value for her clients. Key to Emma’s success is her ability to rapidly distil and simplify complex biological concepts into clear messages, supporting strategic decision-making and effective stakeholder engagement.
Emma has held multiple senior positions from seed-stage biotech to large pharma and has a strong track record of delivery across biologics, small molecule and platform technology projects. She has led projects to ‘Lead’ and ‘Candidate’ selection, identified first-in-class targets, built and managed multi-disciplinary teams and developed drug discovery strategy to support successful fundraising. Emma’s core therapeutic expertise spans Immunology, Oncology and Fibrotic disease, although her key skills can be applied in any disease area.
Industrial career highlights: VP Biology (Nucleome Therapeutics); Head of Discovery (LabGenius); Head/Director of Target Validation (Immunocore); Lab Head/Research Investigator (Novartis)
Keyword list (alphabetical order): AI/Machine Learning-led target discovery platforms; Assay Development; Asthma; Autoimmune Disease; Biologics Drug Discovery; Biomarkers (Exploratory); Candidate Selection; Cellular Pharmacology; Co-Culture Assay; COPD; Crohn’s Disease/IBD; CRO Management; Cystic Fibrosis; Due Diligence; Epithelial Biology; ex vivo Assay; Fibrotic Disease; Fundraising; Genomics-led target discovery platforms; Hematological Malignancy; Human Tissue Authority and GMO Compliance; Idiopathic Pulmonary Fibrosis (IPF); Immunology; Immuno-Oncology; Investor Relations; in vitro Pharmacology; Lead Selection; Molecular Biology; Mucosal Ion Transport; Multiple Sclerosis; Multidisciplinary Teams; Omics-led target discovery (bulk tissue and single cell); Oncology; Patient Selection Assays; Patient Stratification; Pharmacodynamic (PD) markers; Phenotype Screening; Platform Technology Drug Discovery; Precision Medicine; Respiratory Disease; RNA therapeutics; Screening Cascade; Small Molecule Drug Discovery; Solid Tumours; Strategy (disease area/drug discovery); Systemic Lupus Erythematosus (SLE); Target Identification and Validation; TCR/T-cell/Immune cell engagement; Team Leadership (Management, Coaching, Mentoring); Therapeutic Area evaluation; Tissue Remodeling; Tumour Microenvironment; Ulcerative Colitis/IBD.
Accreditations
Scientific images used on this site are provided by Vecteezy.com:
https://www.vecteezy.com/free-photos/biology
https://www.vecteezy.com/free-photos/science
